This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.
PRIMARY OBJECTIVE: 1. To define the most appropriate imaging parameters of 1H MRS for obtaining deuterium-labeled glucose metabolism (Cohorts 1 and 2). 2. To evaluate treatment induced metabolic changes after the administration of 2H-glucose in participants with glioma (Cohort 3). OUTLINE: Participants with and without glioma will be evaluated to develop a robust strategy for obtaining 2H-glucose metabolism in twenty healthy participants (cohort 1) and thirty participants with glioma (cohort 2), while the remaining thirty glioma participants will be studied at baseline and after completion of non-investigational therapy (cohort 3).
Study Type
OBSERVATIONAL
Enrollment
80
Given orally
Imaging procedure performed at University of California, San Francisco
Capillary blood from the fingertip
University of California, San Francisco
San Francisco, California, United States
Signal-to-noise ratio (Cohort 1 & 2)
The signal-to-noise ratio (SNR) in metabolite concentrations will be calculated and compared on a voxel-by-voxel basis and via summary parameters (mean, median, and max) from the regions of interest (ROIs) of the anatomic and metabolic lesions on the imaging scan. Peaks with SNR \> 5.0 are considered detectable
Time frame: Day of imaging (1 day)
Mean difference in metabolite concentrations (Cohort 1 & 2)
Mean difference in metabolite concentrations of 2H labeling of these metabolites will be calculated and compared on a voxel-by-voxel basis and via summary parameters (mean, median, and max) from the ROIs of the anatomic and metabolic lesions.
Time frame: Day of imaging (1 day)
Mean difference in fractional enrichment (Cohort 1 & 2)
Mean difference in fractional enrichment of 2H labeling of these metabolites will be calculated and compared on a voxel-by-voxel basis and via summary parameters (mean, median, and max) from the ROIs of the anatomic and metabolic lesions.
Time frame: Day of imaging (1 day)
Mean metabolic turnover over time (Cohort 3)
Estimates of the extent of change over time following non-investigational treatment obtained at the baseline and one repeated after receiving treatment will be compared.
Time frame: Up to 21 days after the completion of non-investigational treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Imaging procedure performed at University of California, San Francisco